This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-13. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
=== Preclinical development === Several ASOs are currently being investigated in disease models for Alexander disease, ATXN2 (gene) and FUS (gene) amyotrophic lateral sclerosis, Angelman syndrome, Lafora disease, lymphoma, multiple myeloma, myotonic dystrophy, Parkinson's disease, Pelizaeus–Merzbacher disease, and prion disease, Rett syndrome, spinocerebellar Ataxia Type 3.
The related compound and Amanita species constituent ibotenic acid is a prodrug of muscimol, but also has neurotoxic effects. Muscimol was first isolated from Amanita muscaria and hence was discovered in 1964. It has been limitedly clinically studied as a potential pharmaceutical drug for a number of uses, such as treatment of epilepsy. In addition, analogues and derivatives of muscimol, such as the selective GABAA receptor agonist gaboxadol (THIP; LU-2-030) and the selective GABA reuptake inhibitor tiagabine (Gabitril), have been developed as pharmaceutical drugs. Muscimol and Amanita muscaria mushrooms have rarely been used as recreational drugs historically. By the mid-2020s however, use of these substances, including recreational use for hallucinogenic effects and microdosing for claimed therapeutic benefits, has become increasingly prominent. The most commonly cited therapeutic reason for their use is to improve sleep. Muscimol is not a controlled substance and is unregulated in most of the world, including in most of the United States and Europe.
=== 31 January === US President Joe Biden said no to sending F-16s fighter jets to Ukraine after being asked by a reporter. A spokesman for British PM Rishi Sunak said it was not practical for the UK to supply Ukraine with fighter jets. Two US government officials said that the US was preparing a $2 billion aid package to Ukraine which included Ground Launched Small Diameter Bombs with a range of around 150 km (93 mi).
Sources: en.wikipedia.org
Somalia is a federal parliamentary representative democratic republic. The president of Somalia is the head of state and commander-in-chief of the Somali Armed Forces and selects the prime minister to lead as head of government. The Federal Parliament of Somalia is the national parliament of Somalia. The bicameral National Legislature consists of the House of the People (lower house) and the Senate (upper house), whose members are elected to serve four-year terms. The parliament elects the President, Speaker of Parliament and Deputy Speakers. It also has the authority to pass and veto laws. The Judiciary of Somalia is defined by the Provisional Constitution of the Federal Republic of Somalia. Adopted on 1 August 2012 by a National Constitutional Assembly in Mogadishu, the document was formulated by a committee of specialists chaired by attorney and Speaker of the Federal Parliament, Mohamed Osman Jawari. It provides the legal foundation for the existence of the Federal Republic and source of legal authority.
== Former supermarket chains == Carrefour (Taken over by AEON Group to become AEON BiG) Emporium Supermarket & Departmental Store Fajar Supermarket Hiong Kong Supermarket Jaya Supermarket Kimisawa Supermarket Makro (Taken over by Tesco to become Tesco Extra) Ngiu Kee Pasaraya Greatwall Pasaraya Ocean Rich Supermarket Senyum Supermarket Costco Sri Kota Supermarket Tesco (Taken over by Lotus's) Tesco Extra Tops Yaohan Supermarket Kedai Runcit Usaha Kami Yuyi Supermarket
The first ENSO pattern to be recognised, called Eastern Pacific (EP) ENSO, to distinguish it from others, involves temperature anomalies in the eastern Pacific. In the 1990s and 2000s, variations of ENSO conditions were observed, in which the usual place of the temperature anomaly (Niño 1 and 2) is not affected, but an anomaly also arises in the central Pacific (Niño 3.4). The phenomenon is called Central Pacific (CP) ENSO, "dateline" ENSO (because the anomaly arises near the dateline), or ENSO "Modoki" (Modoki is Japanese for "similar, but different"). There are variations of ENSO additional to the EP and CP types, and some scientists argue that ENSO exists as a continuum, often with hybrid types. The effects of the CP ENSO are different from those of the EP ENSO. The El Niño Modoki is associated with more hurricanes more frequently making landfall in the Atlantic. La Niña Modoki leads to a rainfall increase over northwestern Australia and northern Murray–Darling basin, rather than over the eastern portion of the country as in a conventional EP La Niña. Also, La Niña Modoki increases the frequency of cyclonic storms over Bay of Bengal, but decreases the occurrence of severe storms in the Indian Ocean overall. The first recorded El Niño that originated in the central Pacific and moved toward the east was in 1986. Recent Central Pacific El Niños happened in 1986–87, 1991–92, 1994–95, 2002–03, 2004–05 and 2009–10. There were "Modoki" events in 1957–59, 1963–64, 1965–66, 1968–70, 1977–78 and 1979–80.
Sources: en.wikipedia.org
According to the NY-AG, only about 20% of the herbal supplements tested contained the plants claimed. The methodology used by the NY-AG was disputed. The test involves looking for DNA fragments from the plants named as the dietary supplement ingredients in the products. One scientist said that it was possible that the extraction process used to create the supplements removed or destroyed all DNA. This, however, would not explain the presence of DNA from plants such as rice or wheat, that were not listed as ingredients. A study of dietary supplements sold between 2007 and 2016 identified 776 that contained unlisted pharmaceutical drugs, many of which could interact with other medications and lead to hospitalization. 86% of the adulterated supplements were marketed for weight loss and sexual performance, with many containing prescription erectile dysfunction medication. Muscle building supplements were contaminated with anabolic steroids that can lead to health complications affecting the kidney, the heart, and cause gynecomastia. Multiple bodybuilding products also contained antidepressants and antihistamines. Despite these findings, fewer than half of the adulterated supplements were recalled.
Acute inhibition of the lateral habenula, a part of the brain responsible for inhibiting the mesolimbic reward pathway and referred to as the "anti-reward center", is another possible mechanism for ketamine's antidepressant effects. Possible biochemical mechanisms of ketamine's antidepressant action include direct action on the NMDA receptor and downstream effects on regulators such as brain-derived neurotrophic factor (BDNF) and mTOR. It is not clear whether ketamine alone is sufficient for antidepressant action or its metabolites are also important; the active metabolite of ketamine, hydroxynorketamine, which does not significantly interact with the NMDA receptor but nonetheless indirectly activates AMPA receptors, may also or alternatively be involved in the rapid-onset antidepressant effects of ketamine. As an NMDA receptor antagonist, ketamine triggers a paradoxical acute burst of glutamate by selectively blocking inhibitory GABAergic neurons. This surge activates AMPA receptors, which modulate downstream signaling pathways in the limbic system to produce rapid antidepressant effects. Such downstream actions of the activation of AMPA receptors include upregulation of BDNF and activation of its signaling receptor tropomyosin receptor kinase B (TrkB), activation of the mammalian target of rapamycin (mTOR) pathway, deactivation of glycogen synthase kinase 3 (GSK-3), and inhibition of the phosphorylation of the eukaryotic elongation factor 2 (eEF2) kinase.
When the Basilica of Saint-Denis was desecrated by French revolutionaries in 1793, the body of Henry IV was so well preserved it was displayed two days before being thrown in a mass grave, and a new death mask was able to be made. Likewise, Louis XIII was still recognisable thanks to his well preserved moustache. Turenne was so well preserved that looters first thought he was still alive. Maria II of Portugal died in childbirth on 15 November 1853, at the age of 34. Her embalming was conducted the following day and proved to be a complex procedure due to the rapid post-mortem changes in her remains. The Duchess of Ficalho, the queen's lady-in-waiting, provided a primary account of the event in a letter to her brother, the 2nd Count of Lavradio: The sad embalming took place on November 16th, and I was present throughout. The procedure for the Infante and the Queen lasted seven hours. Once that ordeal was over, it was time to dress the body, which was nearly impossible due to the state of dissolution of Her Majesty. Nevertheless, it was done as well as possible, including the placement of the Orders and the Royal Mantle. It was ultimately necessary to close the coffin, for the state of dissolution was beyond description. In 2012, an exhumation of the remains of Amélie of Leuchtenberg (1812–1873), Empress of Brazil, revealed that her body had undergone extensive long-term preservation. Despite being interred for 139 years, the body was found mummified with skin, hair, and internal organs intact.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.